Skott Greenhalgh - Tela Bio Chief Officer
| TELA Stock | USD 2.94 0.07 2.33% |
Insider
Skott Greenhalgh is Chief Officer of Tela Bio
| Age | 56 |
| Address | 1 Great Valley Parkway, Malvern, PA, United States, 19355 |
| Phone | 484 320 2930 |
| Web | https://www.telabio.com |
Tela Bio Management Efficiency
The company has return on total asset (ROA) of (0.4064) % which means that it has lost $0.4064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4204) %, meaning that it created substantial loss on money invested by shareholders. Tela Bio's management efficiency ratios could be used to measure how well Tela Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.65. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Tela Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 278.2 K, whereas Total Assets are forecasted to decline to about 63.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brendan Shook | Paragon 28 | N/A | |
| Geoffrey Rose | Pulmonx Corp | 50 | |
| Shubham Maheshwari | Varex Imaging Corp | 53 | |
| Lauren Cristina | Pulmonx Corp | N/A | |
| Thomas Timbie | Treace Medical Concepts | 66 | |
| Mark CPA | Treace Medical Concepts | 54 | |
| Paul Verrastro | CVRx Inc | 61 | |
| Jason Edie | Paragon 28 | N/A | |
| Joseph Powers | Si Bone | 64 | |
| Ed Joyce | Axogen Inc | N/A | |
| Mazin Sabra | Clearpoint Neuro | 43 | |
| Martha Morrell | Neuropace | 67 | |
| Michelle Missal | Paragon 28 | N/A | |
| Laura MBA | Si Bone | 57 | |
| John Ordway | Sight Sciences | N/A | |
| Tamer MD | TransMedics Group | 55 | |
| Mark Quick | Orthofix Medical | N/A | |
| Eric Pauls | Tactile Systems Technology | 49 | |
| Danilo DAlessandro | Clearpoint Neuro | 38 | |
| John MS | Delcath Systems | 63 | |
| Anthony Dias | Delcath Systems | 57 | |
Management Performance
| Return On Equity | -3.42 | ||||
| Return On Asset | -0.41 |
Tela Bio Leadership Team
Elected by the shareholders, the Tela Bio's board of directors comprises two types of representatives: Tela Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tela. The board's role is to monitor Tela Bio's management team and ensure that shareholders' interests are well served. Tela Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tela Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Taylor Ocasio, General Secretary | ||
| Antony Koblish, President, Cofounder | ||
| Louisa Smith, Investor Officer | ||
| Skott Greenhalgh, Chief Officer | ||
| Peter Murphy, Chief Officer | ||
| Roberto JD, CFO COO | ||
| Megan Smeykal, Corporate VP | ||
| Gregory Firestone, Chief Officer | ||
| Michael Leonard, Senior Operations | ||
| Jennifer Armstrong, Senior Resources | ||
| Paul Talmo, Chief Officer | ||
| Christopher Smith, VP Sales |
Tela Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tela Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.42 | ||||
| Return On Asset | -0.41 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 142.79 M | ||||
| Shares Outstanding | 39.39 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 51.72 % | ||||
| Number Of Shares Shorted | 478.72 K | ||||
| Price To Book | 22.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tela Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tela Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tela Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tela Bio Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.69) | Revenue Per Share 2.789 | Quarterly Revenue Growth 0.259 | Return On Assets (0.41) | Return On Equity (3.42) |
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.